167 related articles for article (PubMed ID: 33793091)
1. A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):671-683. PubMed ID: 33793091
[TBL] [Abstract][Full Text] [Related]
2. A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.
Chen W; Boras B; Sung T; Yu Y; Zheng J; Wang D; Hu W; Spilker ME; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):163-182. PubMed ID: 32162138
[TBL] [Abstract][Full Text] [Related]
3. Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
AAPS J; 2020 Nov; 22(6):143. PubMed ID: 33156437
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
6. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
10. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
12. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF.
Harrold J; Gisleskog PO; Delor I; Jacqmin P; Perez-Ruixo JJ; Narayanan A; Doshi S; Chow A; Yang BB; Melhem M
Pharm Res; 2020 May; 37(6):102. PubMed ID: 32440783
[TBL] [Abstract][Full Text] [Related]
15. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.
Li Y; Klippel Z; Shih X; Wang H; Reiner M; Page JH
Cancer Chemother Pharmacol; 2016 Apr; 77(4):703-12. PubMed ID: 26886017
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF).
Lord BI; Woolford LB; Molineux G
Clin Cancer Res; 2001 Jul; 7(7):2085-90. PubMed ID: 11448927
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
[TBL] [Abstract][Full Text] [Related]
18. The use of granulocyte colony-stimulating factors following peripheral blood progenitor cell rescue after high-dose chemotherapy for advanced breast cancer: a prospective study.
Dazzi C; Albertazzi L; Rosti G; Maestri A; Fiorentini G; Leoni M; Tienghi A; Turci D; Ferrante P; Vertogen B; Cariello A; Latino W; Zumaglini F; Marangolo M
Tumori; 1997; 83(6):900-3. PubMed ID: 9526580
[TBL] [Abstract][Full Text] [Related]
19. PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Yoo N; Lee HR; Shin SH; Sohn KY; Kim HJ; Han YH; Chong S; Kim MH; Yoon SY; Kim JW
Cancer Lett; 2016 Jul; 377(1):25-31. PubMed ID: 27105612
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
